Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome
Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome
Treatment of obesity related to Polycystic Ovary Syndrome with topiramate or placebo to
 assess improvement of clinical and laboratory parameters after 6 months of follow-up
Randomized double blind placebo-controlled clinical trial. Polycystic ovary syndrome (PCOS)
 is a frequent endocrinopathy, affecting more than 10% of women of reproductive age. It is
 associated with a higher prevalence of obesity and insulin resistance, with a higher risk for
 diabetes, dyslipidemia and hypertension. Topiramate is a drug used in the treatment of
 epilepsy and migraine prophylaxis since the 1990s and several studies show an association
 with weight loss. This medicine is administered in combination with phentermine in other
 countries, with variable weight loss. Despite evidence of the benefit of topiramate for
 weight loss, there is still no record of studies evaluating this drug in patients with PCOS
 for the treatment of obesity. The objective of this project is to evaluate the results of
 treatment with topiramate in terms of weight reduction, reduction of serum androgens and
 changes in body composition, in patients with PCOS and obese, associated with a low-calorie
 diet, over a period of six months. Eighty patients with PCOS (18 to 40 years old) seen at the
 HCPA Endocrinology Service outpatient clinic who are overweight with a BMI> or = 27 kg / m2
 associated with at least one comorbidity or obesity (BMI 30-40) will be included. Patients
 will be randomized to 2 groups: Topiramate and Placebo and the 2 groups will receive a
 low-calorie diet.

 Anthropometric, clinical, hormonal, nutritional and body composition assessment will be
 performed before, during and after treatments. It is expected to determine whether the
 addition of topiramate to dietary treatment can improve metabolic, hormonal and weight loss
 outcomes in women with PCOS.

 Research Objective: General objective: To evaluate the results of treatment with topiramate
 in patients with PCOS and obese, associated with a low-calorie diet, in six months of
 treatment.

 Specific objectives: To evaluate the response to the proposed treatment in terms of weight
 reduction and body mass index (BMI), reduction of serum androgens, changes in body
 composition, in addition to assessing minor psychiatric disorders possibly associated through
 the Self-Reporting screening questionnaire. Questionnaire (SRQ-20).

 Assessment of Risks and Benefits: The risks of the project are mainly related to the use of
 the drug topiramate. This drug has an extensive list of adverse effects, in addition to the
 side effect on appetite and weight, the most common are paresthesias, drowsiness, lethargy,
 attention disorder, mood disorders, depression, taste changes and psychomotor disorders.
 However, studies show that the majority of adverse reactions were mild to moderate in
 severity. Other risks inherent to the study are the absence of previous studies in the target
 population and discomfort in relation to the number of visits, additional tests and blood
 samples for an extended period of 6 months. The benefits of the study are related to the
 acquisition of knowledge and the likely positive results may benefit future patients.
Inclusion Criteria:

 -  age between 18 and 40 years

 -  diagnostic criteria for PCOS

 -  overweight with a BMI ≥ 27 kg / m² associated with at least one comorbidity
 (hypertension, type 2 diabetes mellitus, dyslipidemia) or obesity with a BMI between
 30 and 45 kg / m² with or without comorbidities

 Exclusion Criteria:

 -  severe systemic arterial hypertension (≥180 / 100 mmHg)

 -  pregnant or lactating women

 -  diabetics using sulfonylurea or insulin

 -  any known allergy or intolerance to topiramate medication